Health & Beauty

On the 29th local time, the final verification committee of the Korea Food and Drug Safety Administration decided to issue a drug approval number to the new crown vaccine developed by SK Bioscience.

The Department of Food and Drug Safety held a final verification committee meeting that morning to discuss the licensing issue of SK Bioscience's new crown vaccine GBP510, and decided to approve the vaccine for use.

According to reports, the new crown vaccine GBP510 has been approved for use by adults over the age of 18, with a total of two doses. The vaccine is produced entirely in Korea from raw materials to finished products. Clinical trials are conducted in South Korea, New Zealand, the Philippines and other countries.

Before obtaining the license for use, the new crown vaccine GBP510 has undergone triple deliberation by the safety and efficacy verification advisory group, the Central Pharmacist Review Committee, and the Final Verification Committee.

The new crown vaccine developed by SK Bioscience has obtained the drug approval number, which indicates that South Korea is fully equipped with the ability to independently develop and produce new crown treatment drugs and vaccines.